Navigation Links
Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
Date:6/1/2009

--Data from Phase 3 REDUCE-1 and REDUCE-2 Studies Demonstrate that Novel Combination Treatment Decreases Risk of Developing GI Ulcers by Approximately 50 Percent--

--Data presented today at 56th Annual Digestive Disease Week Meeting in Chicago--

CHICAGO, June 1 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented data at the 56th Annual Digestive Disease Week (DDW) meeting from two pivotal Phase 3 trials evaluating its lead compound HZT-501, which demonstrated that patients with mild-to-moderate pain treated with HZT-501 developed 50 percent less NSAID-induced upper gastrointestinal (GI) ulcers (gastric and/or duodenal ulcers) compared to patients treated with ibuprofen alone. HZT-501 is a novel, proprietary fixed-dose combination tablet containing the most prescribed non-steroidal anti-inflammatory drug (NSAID), ibuprofen, and famotidine, the most potent H2 antagonist.

"NSAIDs, such as ibuprofen, are among the most widely used drugs in the world," said Loren Laine, MD, professor of medicine, University of Southern California. "NSAIDs are effective at treating pain, but they also increase the risk of developing ulcers in the stomach or intestine and the risk of developing ulcer complications, such as bleeding. Patients at increased risk for gastrointestinal ulcers may benefit from protective co- therapy, although many such patients do not receive or adhere to this co-therapy."

The presentation at DDW included data from more than 1,300 evaluable patients who participated in the Registration Endoscopic Study to Determine Ulcer Formation of HZT-501 Compared to Ibuprofen: Efficacy and Safety Study, or REDUCE-1 and REDUCE-2. The primary objective of these studies was to evaluate the proportion of patients treated with HZT-501 (800 mg ibuprofen a
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
2. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
3. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
4. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
5. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
6. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Israel , June 19, 2013 ... a phase I study in volunteers, and preliminary results ... of ND0612, were presented at the 2013 International Congress ... proprietary levodopa/carbidopa liquid drug formula under development for continuous ... maintain constant levodopa plasma concentrations. ND0612 has ...
(Date:6/19/2013)...   Life Technologies Corporation (NASDAQ: ... Suzhou Ribo Life Sciences (Ribo) the exclusive rights ... China using Life,s Invivofectamine® Rx ... in combination with Invivofectamine® Rx to create a ... high unmet medical need in the Chinese healthcare ...
(Date:6/19/2013)... Juni 2013 Specialty Coating ... Entwicklung von SCS microRESIST™, einer antimikrobiellen ... Beschichtung mit Parylene gelungen ist. SCS ... Parylene mit antimikrobiellen Eigenschaften und erlaubt ... auf beschichteten medizinischen Geräten. ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... TARRYTOWN, N.Y. and BERLIN, April 8, 2011 ... and Bayer HealthCare today announced that they have initiated ... the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic ... certain eye diseases, in the treatment of Diabetic Macular ...
... Texas, April 7, 2011 Assured Pharmacy (APHY: pinksheets), ... more than 3,000 sufferers of chronic pain, has filed ... to effect a 1-for-180 reverse stock split of the ... reverse stock split in the number of issued and ...
Cached Medicine Technology:Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 2Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 3Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 4Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 5Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 6Assured Pharmacy Announces Reverse Stock Split 2Assured Pharmacy Announces Reverse Stock Split 3
(Date:6/19/2013)... CCA , America's leader in partnership corrections, ... President, Health Services, effective June 8, 2013. Dr. ... CCA. He will replace the retiring Herb Spiwak. ... lead CCA's dedicated team of health care professionals. ... our partners as we provide effective care to persons ...
(Date:6/19/2013)... Chrysler made news recently when it refused ... million Jeeps. The Jeep models in question are the 1993-2004 ... to the NHTSA are vulnerable to fire and explosion in ... are rear-mounted and have been alleged to catch fire or ... Cherokee with 32 rear-end crashes, which resulted in 44 deaths ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 According to a ... Surviving Weekend Sunburn,” it is not uncommon for a person ... summer months. A person is likely to forget to reapply ... which is both dry and itchy. When this occurs, it ... to goo.gl/gDyjP). , “Most people do not realize that milk ...
(Date:6/19/2013)... online edition of the journal Nature , a ... California, San Diego School of Medicine visually monitored the ... occurs in zebrafish after cardiac ventricular injury. Their ... heart are more plastic, or capable of transformation into ... the research reveals a novel potential source of cells ...
(Date:6/19/2013)... Spanish . ... goes by the name of the 10/90 gap: only 10 ... that accounted for 90 per cent of the global disease ... for Neglected Diseases initiative (DNDi) came into being in 2003. ... granted the BBVA Foundation Frontiers of Knowledge Award in the ...
Breaking Medicine News(10 mins):Health News:CCA Names Dr. John Baxter Vice President, Health Services 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:Skin Care – How to treat Sunburn 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5
... French . , Montreal, March 11, 2009 ... influence of cannabis (DUIC) and engage in reckless driving, according ... the journal Accident Analysis and Prevention , men who ... consider taking the wheel after consuming cannabis more often than ...
... 11 On Friday, March 6, 2009, Coast ... Justice, the FBI, the FDA, and the Commonwealth of Virginia ... Independent Review Board discovered that a protocol submitted for review ... of Clifton, Virginia, was fraudulent in violation of federal and ...
... most progressive benefit management firms, today announced a strategic partnership with ... will enable CBCA to provide an unparalleled suite of proven care ... ... OH (Vocus) March 11, 2009 -- CBCA Administrators, Inc. (CBCA), one ...
... LOS ANGELES, March 11 MMR Information ... through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ... Records ("PHRs") ( www.mymedicalrecords.com ) and electronic ... ), announced that it has selected Gene ...
... March 11 The U.S. Agency for ... in Southern Africa launched a new program to reduce ... and Mpumalanga Provinces. The three-year, $5.1 million project is ... Relief (PEPFAR), and administered by USAID . A ...
... researchers wanted to know whether an increased CO2 ... therefore examined freshwater micro-algae: small, floating and mostly ... tanks called limnotrons. These were aerated with ordinary ... of CO2. The researchers then examined the ratio ...
Cached Medicine News:Health News:Study finds cannabis use, dangerous driving behaviors interrelated 2Health News:Clinical Trial Fraud Exposed by Coast IRB 2Health News:CBCA Administrators, Inc. Announces Strategic Partnership with KePRO 2Health News:CBCA Administrators, Inc. Announces Strategic Partnership with KePRO 3Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 2Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 3Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 4Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 5Health News:USAID and IOM Announce HIV Prevention and Care for Farm Workers 2
Each handle is designed to fit a specific trephine size....
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
Medicine Products: